Related Experiment Video

Updated: Jul 17, 2026

Drug Treatment and In Vivo Imaging of Osteoblast-Osteoclast Interactions in a Medaka Fish Osteoporosis Model
08:53

Drug Treatment and In Vivo Imaging of Osteoblast-Osteoclast Interactions in a Medaka Fish Osteoporosis Model

Published on: January 1, 2017

[Therapeutic agents for disorders of bone and calcium metabolism: Minodronic acid hydrate]

Takashi Miki1, Toshiomi Minamide

  • 1Ono Pharmaceutical Co., Ltd., Clinical Planning III Development Planning.

Clinical Calcium
|January 11, 2007
PubMed

Insights

Minodronic acid hydrate effectively reduces vertebral fracture risk in postmenopausal osteoporosis patients. This nitrogen-containing bisphosphonate demonstrates comparable bone mineral density increases and a favorable safety profile, making it a promising osteoporosis treatment.

Area of Science:

  • Pharmacology
  • Bone Biology
  • Drug Development

Context:

  • Osteoporosis is a significant health concern, particularly in postmenopausal women.
  • Current treatments aim to inhibit bone resorption and improve bone density.
  • Minodronic acid hydrate represents a new generation of nitrogen-containing bisphosphonates.

Purpose:

  • To evaluate the efficacy and safety of minodronic acid hydrate in treating osteoporosis.
  • To assess its effect on bone mineral density, bone intensity, and fracture risk.

Summary:

  • Minodronic acid hydrate demonstrated efficacy in preclinical models of osteoporosis.
  • Phase III studies showed a reduced risk of vertebral fractures in postmenopausal Japanese women with osteoporosis after 104 weeks of daily administration.
  • It also increased bone mineral density comparably to alendronate over 48 weeks.
  • Safety analysis indicated no statistically significant difference in adverse events compared to placebo.

Impact:

  • Minodronic acid hydrate shows potential as a potent and safe therapeutic option for osteoporosis.
  • Its domestic development offers a new domestic bisphosphonate choice for patients.
  • Expected to be widely adopted for osteoporosis management in the near future.

More Related Videos

A Novel in vivo Gene Transfer Technique and in vitro Cell Based Assays for the Study of Bone Loss in Musculoskeletal Disorders11:47

A Novel in vivo Gene Transfer Technique and in vitro Cell Based Assays for the Study of Bone Loss in Musculoskeletal Disorders

Published on: June 8, 2014

Related Concept Videos

Bone Disorders01:29

Bone Disorders

Aging and its effect on bone remodeling is the most common cause of bone disorders. In young and healthy people, bone deposition and resorption happen at an equal rate to maintain optimal bone health.
Bone deposition is also affected by the levels of sex hormones like estrogen and testosterone that promote osteoblast activity and bone matrix synthesis. When the level of these hormones decreases due to aging, it causes a reduction in bone deposition. As a result, bone resorption by osteoclasts...
Antianginal Drugs: Calcium Channel Blockers and Ranolazine01:25

Antianginal Drugs: Calcium Channel Blockers and Ranolazine

Angina pectoris, a primary symptom of ischemic heart disease, requires careful pharmacological interventions. In this context, calcium channel blockers (CCBs) and ranolazine have emerged as crucial pharmacotherapeutic agents, providing deep insights into the complexities of angina management.
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
Directly Acting Muscle Relaxants: Dantrolene and Botulinum Toxin01:26

Directly Acting Muscle Relaxants: Dantrolene and Botulinum Toxin

Directly acting muscle relaxants like dantrolene and botulinum toxin (BoNT) have distinct mechanisms and applications. Dantrolene, a hydantoin derivative, acts on the ryanodine receptor (RYR1) in skeletal muscle cells. RYR1 are calcium channels present at the sarcoplasmic reticulum membrane. In response to excitation, they release calcium ions from the sarcoplasmic reticulum to the cytosol. Calcium promotes actin-myosin-mediated contraction of muscles.
The binding of dantrolene to the RYR1...
Essential Minerals for Bone Health01:31

Essential Minerals for Bone Health

The minerals contained in all of the food we consume are essential for our organ systems. However, certain essential minerals, such as calcium, phosphorus, magnesium, manganese, and fluoride, largely affect bone health.
Calcium and Phosphorus
Calcium is a critical component of bones, especially in the form of calcium phosphate and calcium carbonate. Since the body cannot make calcium, it must be obtained from the diet. However, calcium cannot be absorbed from the small intestine without...
Antihypertensive Drugs: Action of Calcium Channel Blockers01:18

Antihypertensive Drugs: Action of Calcium Channel Blockers

Calcium ions are essential to contract smooth muscle cells in blood vessels. They enter these cells through voltage-dependent calcium channels, specifically L-type calcium channels in the cell membrane. These L-type calcium channels are integral to the excitation-contraction coupling process in smooth muscle. When a stimulus is received by smooth muscle cells, their membrane depolarizes. This alteration in membrane potential instigates the opening of L-type calcium channels. As a result,...
Antiarrhythmic Drugs: Class IV Agents as Calcium Channel Blockers01:20

Antiarrhythmic Drugs: Class IV Agents as Calcium Channel Blockers

Class IV antiarrhythmic drugs, such as verapamil and diltiazem, block calcium channels. They primarily affect the heart, slowing the conduction in calcium-dependent tissues like the SA and AV nodes. These drugs manage reentrant supraventricular tachycardia (SVT) and reduce ventricular rate in atrial flutter/fibrillation.
Verapamil, a calcium channel blocker, inhibits calcium movement across myocardial cell membranes and vascular smooth muscle. This results in the dilation of coronary and...